PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) today announced the presentation of clinical research from its hematology portfolio at the 57th Annual Meeting & Exposition of the American Society of Hematology (ASH) in Orlando, FL, December 5-8. Bristol-Myers Squibb will present data for elotuzumab, an investigational immunostimulatory antibody, in patients with relapsed or refractory (R/R) multiple myeloma (MM); for Opdivo (nivolumab) for an investigational use in patients with R/R classical Hodgkin lymphoma (cHL); and for Sprycel (dasatinib) in chronic myeloid leukemia (CML).
